홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Dienogest

HCID 178955264
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
2376035-92-4
표준 SMILES
C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N
InChIKey
AZFLJNIPTRTECV-FUMNGEBKSA-N
분자식
C20H25NO2
평균 분자량
311.4 g/mol

개요

Dienogest is a steroid hormone that is 17beta-hydroxy-3-oxoestra-4,9-diene substituted at position 17 by a cyanomethyl group. Used as an oral contraceptive. It has a role as a synthetic oral contraceptive, a progestin and a progesterone receptor agonist. It is a steroid hormone, a 17beta-hydroxy steroid, a 3-oxo-Delta(4) steroid and an aliphatic nitrile. It derives from a hydride of an estrane.

이름 및 식별자

우선 이름
Dienogest
IUPAC
2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile
영어명
Dienogest-d8
분자식
C20H25NO2
분자량
311.43

이름 및 동의어

Dienogest65928-58-7DienogestrilDienogestumEndometrionSTS 557STS-557MJR-3517alpha-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile46M3EV8HHEZK 37659M 18575
이름 더 보기
Dienogest-d817α-hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile-2,2,4,8,11,11,20,20-d8
M-1857517-alpha-Cyanomethyl-17-beta-hydroxy-estra-4,9(10)-dien-3-one19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17alpha)-ZK-37659CHEBI:7070817-Hydroxy-3-oxo-19-nor-17alpha-pregna-4,9-diene-21-nitrileDTXSID8089147819-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17-alpha)-

데이터베이스 식별자

CAS
2376035-92-4
ChEMBL
CHEMBL1201864
ChEBI
CHEBI:70708
UNII
46M3EV8HHE
EC Number
639-448-2
Nikkaji
J23.763I

물성

구조 계산 물성보충 중

XLogP
1.8
극성 표면적
61.1 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
3
회전 가능 결합 수
1
무거운 원자 수
23
형식 전하
0
복잡도
679

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
SolubilityPractically insoluble
Human Drugs · 3건

Breast Feeding; Lactation; Milk, Human; Contraceptive Agents, Female; Contraceptives, Oral, Synthetic

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point210-218

물리화학적 성질

저장 조건
-20 °C · Store at -20°C
용해도
Chloroform: slightly soluble,Methanol: slightly, sonicated
물리적 상태
고체

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H315 (10%): Causes skin irritation [Warning Skin corrosion/irritation]

P203, P260, P261, P263, P264, P264+P265, P270, P271, P273, P280, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 10 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesSkin Irrit. 2 (10%)

독성 정보

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

화학 및 산업

약리 정보

ATC Code · 3건

G03DB08

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

Protein BindingDienogest is 90% nonospecifically bound to albumin. It displays no binding to sex hormone binding globulin (SHBG) or corticoid binding globulin (CBG).
Pharmacodynamics · 1건

Dienogest exhibits a very potent progestagenic effect in the endometrium, and causes endometrial atrophy after prolonged use . It also mediates an antiandrogenic effect that is equivalent to approximately one third that of cyproterone acetate. A dose of 2 mg inhibits the growth of ovarian follicles at 10 mm and maintains the concentration of progesterone at a low level, but has a weak inhibitory effect on FSH and LH. 1mg/kg of dienogest also directly inhibits ovulation. In clinical trials composing of patients with endometriosis, dienogest therapy effectively reduced painful symptoms and endometriotic lesions associated with the disorder. Dienogest displays no antiestrogenic activity as it activate neither estrogen receptor (ER) α nor ERβ, and causes hypoestrogenic effects instead as it is shown to decrease the relative expressions of ERβ and ERα. It has no glucocorticoid or mineralocorticoid effects. In combined oral contraceptive pills (COCP) with ethinyloestradiol, dienogest conjuction therapy effectively reduces the symptoms of acne and hirsutism, as well as improving excessively heavy or prolonged menstrual bleeding.

Mechanism of Action · 1건

Dienogest acts as an agonist at the progesterone receptor (PR) with weak affinity that is comparable to that of progesterone but has a very potent progestagenic effect in the endometrium, causing endometrial atrophy after prolonged use. It promotes antiproliferative, immunologic and antiangiogenic effects on endometrial tissue. Dienogest reduces the level of endogenous production of oestradiol and thereby suppressing the trophic effects of oestradiol on both the eutopic and ectopic endometrium. Continous administration of dienogest results in hyperprogestogenic and moderately hypoestrogenic endocrine environment, which causes initial decidualization of endometrial tissue. It is an antagonist at androgen receptors, improve androgenic symptoms such as acne and hirsutism.

관련 반응

0건
반응 기록 만들기
아직 관련 반응이 없습니다

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
Biological Half-LifeElimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours.
Metabolism/MetabolitesDienogest undergoes complete metabolism that is mainly mediated by CYP3A4. The metabolites are pharmacologically inactive and rapidly eliminated from the plasma.
FDA Pharmacological Classification · 5건

46M3EV8HHE

DIENOGEST

Established Pharmacologic Class [EPC] - Progestin

Chemical Structure [CS] - Progesterone Congeners

Dienogest is a Progestin.

MeSH Pharmacological Classification · 4건

Chemical substances or agents with contraceptive activity in males. Use for male contraceptive agents in general or for which there is no specific heading.

Oral contraceptives which owe their effectiveness to hormonal preparations.

Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Absorption, Distribution and Excretion · 4건

Dienogest is rapidly absorbed following oral administration, with 91% bioavailability. The peak plasma concentration of 47 ng/mL is reached at about 1.5 hours after single ingestion of 2 mg. The stable concentrations of the drug are reached after two days of initial treatment.

The ratio of renal elimination to fecal elimination of dienogest is 3:1, where dienogest is predominantly excreted in the form of inactive metabolites. Most of orally administered drug is excreted in the urine within the first 24 hours of ingestion.

The apparent volume of distribution (Vd/F) of dienogest is 40 L.

The metabolic clearance rate from serum (Cl/F) is 64 mL/min.

용도 및 제조

UsesUse (kg; approx.) in Germany (2009): >500